课题基金 / 基金详情

Pipe-line for rapid screening and rational improvement of nanoparticles for cancer imaging and therapy

Pipe-line for rapid screening and rational improvement of nanoparticles for cancer imaging and therapy
用于癌症成像和治疗的纳米颗粒的快速筛选和合理改进的管道
批准号:
ST/K001957/1
负责人:
Fred Currell
金额:
$5.63万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2012
资助国家:
英国
项目状态:
已结题
起止时间:
2012 至 --

项目摘要

项目成果

Fred Currell的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Heavy ion beam radiotherapy has been shown to be a highly effective way to treat many types of cancer, both in Japan and Germany. However, this approach requires large, expensive facilities of a kind not currently foreseen in the UK. There are two reasons for this approach being so effective:i) Because the ions in these beams deposit most of their energy just before they come to rest, they can be used to pick out each part of the tumour in turn, with the patient suffering much lower side effects than those associated with traditional approaches, i.e. their effect is highly targeted. ii) Each ion in the beam gives a 'punch' to the cells it passes through just before it stops. This punch is much more intense and highly focused than photons used in traditional radiotherapy. This localised punch can knock out even the most resistant cell.In summary, these heavy ions deliver a series of 'targeted punches' right to the diseased cells. Carefully designed gold nanoparticles have the potential to offer both of these benefits, delivering this same series of targeted punches at traditional radiotherapy centres such as those we have across the UK. Whilst offering a realistic and economic alternative to heavy ion therapy they can also offer additional benefits.To realise this approach, these particles would be given a chemical 'cloak' that will allow them to pass through the patient's body to the tumour. They would also be given a chemical 'key' which will recognize and preferentially allow them to enter the diseased cells. They might also be given other keys to pass into critical regions of the cell (e.g. the nucleus). Once inside the diseased cells, their presence can be detected in a CT scan to show where the tumour is located. Furthermore, during traditional radiotherapy (using linacs), they can take a large fraction of the energy in the X-ray beam and turn it into the same kind of highly focused punch that has proved so effective in ion beam radiotherapy, destroying the cancerous cells while leaving the healthy ones largely unaffected. We have revealed the mechanism whereby these nanoparticles give the same punch as the heavy ions used so successfully in Germany and Japan. We also have developed a technique to rapidly image them within cells. The particular feature of our imaging approach is that it measures the presence of the gold core directly rather than some other tag which has been placed upon it. This is important because the tag can detach giving misleading results in other approaches.The next step in making this therapy effective is to try gold nanoparticles of various sizes, various 'cloak' constructions and equipped with different 'keys' with a view to optimizing their uptake into cancerous cells whilst minimizing it for healthy cells. We will develop a pipeline built around our new imaging technique to assess the degree of uptake and localization of the gold nanoparticles, thereby assessing their suitability. Furthermore, our imaging technique can be used to show if the gold nanoparticles are clumping together in the cells (a common problem). Using this pipeline we will rapidly determine the optimum size of the gold nanoparticles, suitable cloaking constructions and a set of 'keys' to provide entry into the diseased cells. Furthermore, we will extend the imaging technique to image live cells as they take up the nanoparticles, providing very useful information for improving their design in a rational way.The optimized nanoparticle designs coming from the pipeline will be suitable to be taken forward into bigger research projects and clinical trials where their full potential for treating various cancers will be determined. Hence, this project will act as a springboard from which an entirely new approach to treating cancer will emerge.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1186/s12645-016-0025-6
发表时间: 2017
期刊: Cancer nanotechnology
影响因子: 5.7
作者: [Brown JMC, Currell FJ]
通讯作者: Currell FJ
DOI: 10.1259/bjr.20150170
发表时间: 2015-10
期刊: The British journal of radiology
影响因子: --
作者: [Botchway SW, Coulter JA, Currell FJ]
通讯作者: Currell FJ
DOI: 10.1186/s12645-016-0014-9
发表时间: 2016
期刊: Cancer nanotechnology
影响因子: 5.7
作者: [Currell F, Bellringer M]
通讯作者: Bellringer M
Gold nanoparticles and alchemy: making photons behave like heavy ions
金纳米粒子和炼金术:使光子表现得像重离子
DOI: --
发表时间: 2012
期刊: MUTAGENESIS
影响因子: 2.7
作者: [Currell Fred J.]
通讯作者: Currell Fred J.
9
    Enhancing Materials Irradiations through Thoughtful Shielding (EMITS)
    • 批准号:
      EP/V035673/1
    • 项目类别:
      Research Grant
    • 资助金额:
      $87.36万
    • 财政年份:
      2021
    • 负责人:
      Fred Currell
    • 依托单位:
    Clinical Adaptive Radiation Transport Algorithms (CARTA)
    • 批准号:
      EP/R030677/1
    • 项目类别:
      Research Grant
    • 资助金额:
      $28.78万
    • 财政年份:
      2019
    • 负责人:
      Fred Currell
    • 依托单位:
    Radiation and Us: Visualising the Invisible
    • 批准号:
      EP/F06652X/1
    • 项目类别:
      Research Grant
    • 资助金额:
      $12.38万
    • 财政年份:
      2008
    • 负责人:
      Fred Currell
    • 依托单位:
    Software-controlled assembly of oligomers
    • 批准号:
      EP/F00740X/1
    • 项目类别:
      Research Grant
    • 资助金额:
      $1.26万
    • 财政年份:
      2007
    • 负责人:
      Fred Currell
    • 依托单位:
    国内基金
    海外基金
    piRNA DQ689086丢失激活LINE1 ORF2p的表达促进苔藓细胞死亡
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      黄和周
    • 依托单位:
    人基因组中LINE-1与OR4K15核酶结构与功能研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      15.0万元
    • 批准年份:
      2024
    • 负责人:
      黄林
    • 依托单位:
    骨髓微环境细胞中LINE-1促进血细胞恶变的机制研究
    • 批准号:
      82370184
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      顾志敏
    • 依托单位:
    LINE-1转座子在小鼠神经系统中的功能和机制研究
    • 批准号:
      32300448
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      20万元
    • 批准年份:
      2023
    • 负责人:
      别路垚
    • 依托单位: